

THE AMERICAN JOURNAL OF PSYCHIATRY

STAR*D Algorithm

LEVEL 1

INITIAL TREATMENT:
citalopram

LEVEL 2

SWITCH TO: bupropion
(sustained-release), cognitive
therapy, sertraline,
venlafaxine (extended-
release)

OR AUGMENT WITH:
bupropion (sustained-
release), buspirone, cognitive
therapy

LEVEL 2A

(only for those
receiving cognitive
therapy in Level 2)

SWITCH TO:
bupropion
(sustained-release)
or venlafaxine
(extended-release)

LEVEL 3

SWITCH TO: mirtazapine or
nortriptyline

OR AUGMENT WITH:
lithium or triiodothyronine
(only with bupropion
[sustained-release],
sertraline, venlafaxine
[extended-release])

LEVEL 4

SWITCH TO: tranylcypromine
or mirtazapine combined
with venlafaxine (extended-
release)

SSRI-Associated Sexual Dysfunction

Richard Balon

1504

A Comparison of Lithium and T₃ Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report

Andrew A. Nierenberg et al.

1519

Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report

Patrick J. McGrath et al.

1531

Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers

Ronald C. Kessler et al.

1561

Continuing Medical Education

1664

September 2006

Volume 163 • Number 9

Official Journal of the
AMERICAN PSYCHIATRIC ASSOCIATION

ajp.psychiatryonline.org